Target Gene/Pathway
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * | DrugBank | Disease ID * [Number of diseases] |
1 | Acute myeloid leukemia |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
2 | Adipocytokine signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
3 | Adrenergic signaling in cardiomyocytes |
[2] ADRB1, ADRB2 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
4 | AMPK signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
5 | Apelin signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
6 | Autophagy - animal |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
7 | Autophagy - other |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
8 | Breast cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
9 | Calcium signaling pathway |
[3] ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
10 | cAMP signaling pathway |
[2] ADRB1, ADRB2 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
11 | Cellular senescence |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
12 | Central carbon metabolism in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
13 | cGMP-PKG signaling pathway |
[3] ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
[1] PDE5A | D02229 | Sildenafil | [16] 6, 46, 50, 51, 85, 86, 96, 113, 210, 211, 212, 225, 226, 278, 294, 299 | ||
D08514 | |||||
14 | Choline metabolism in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
15 | Colorectal cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
16 | Dilated cardiomyopathy (DCM) |
[1] ADRB1 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
17 | EGFR tyrosine kinase inhibitor resistance |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
18 | Endocrine resistance |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
19 | ErbB signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
20 | Gap junction |
[1] ADRB1 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
21 | Gastric cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
22 | Glioma |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
23 | Growth hormone synthesis, secretion and action |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
24 | Hepatocellular carcinoma |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
25 | Herpes simplex virus 1 infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
26 | HIF-1 signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
27 | Human cytomegalovirus infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
28 | Human immunodeficiency virus 1 infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
29 | Human papillomavirus infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
30 | Insulin resistance |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
31 | Insulin signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
32 | JAK-STAT signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
33 | Kaposi sarcoma-associated herpesvirus infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
34 | Longevity regulating pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
35 | Longevity regulating pathway - multiple species |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
36 | Metabolic pathways |
[1] PDE5A | D02229 | Sildenafil | [16] 6, 46, 50, 51, 85, 86, 96, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
D08514 | |||||
37 | MicroRNAs in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
38 | mTOR signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
39 | Neuroactive ligand-receptor interaction |
[3] ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
40 | Pancreatic cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
41 | Pathways in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
42 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
43 | Phospholipase D signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
44 | PI3K-Akt signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
45 | Prostate cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
46 | Proteoglycans in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
47 | Purine metabolism |
[1] PDE5A | D02229 | Sildenafil | [16] 6, 46, 50, 51, 85, 86, 96, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
D08514 | |||||
48 | Regulation of lipolysis in adipocytes |
[3] ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
49 | Renin secretion |
[3] ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
50 | Salivary secretion |
[3] ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
51 | Shigellosis |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
52 | Th17 cell differentiation |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
53 | Thermogenesis |
[1] ADRB3 | D00483 | Propranolol | [5] 6, 158, 167, 227, 278 |
D08443 | |||||
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
54 | Thyroid hormone signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
55 | Type II diabetes mellitus |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |